Recovery from laparo-endoscopic single-site surgery (LESS) was less painful for kidney cancer patients than traditional laparoscopic surgery, according to a recent study by University of California, San Diego researchers.
Phase 3 ARASTEP study to investigate darolutamide plus ADT for hormone-sensitive prostate cancer
"With ARASTEP, we are optimistic about the potential to help patients at this earlier stage of [prostate cancer]," says Tara Frenkl, MD.
Dr. Kishan highlights findings from the MIRAGE trial in prostate cancer
Amar Kishan, MD, highlights findings showing that MRI-guided SBRT is superior to CT-guided SBRT in localized prostate cancer.
Hormone therapy plus current treatments improves survival in prostate cancer
Darolutamide increased overall survival compared to placebo in the overall patient population and patients with high-volume, high-risk mHSPC as well as in patients with low-risk metastatic hormone-sensitive prostate cancer.
Speaking of Urology: ASCO GU 2023 Highlights
Laura Bukavina, MD, and Kyle Rose, MD, discuss some of the notable abstracts from the 2023 ASCO GU conference.
Urologist Ash Tewari appointed Surgeon-in-Chief of Tisch Cancer Hospital
Ash Tewari, MBBS, MCh, is Chair of the Milton and Carroll Petrie Department of Urology at the Icahn School of Medicine at Mount Sinai.
Dr. Dallos discusses emerging treatments in the mCRPC paradigm
Antibody-drug conjugates, including those targeting PSMA, are among the next wave of treatment advances in mCRPC.
2 Clarke Drive Cranbury, NJ 08512